Table 4. Univariate and multivariate analyses of pre-S deletion regions for recurrence-free survival in 75 HBV-related HCC patients.
| Characteristics | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age (years) (>50 vs. ≤50) | 0.951 | 0.532–1.700 | 0.8666 | |||
| Gender (men vs. women) | 1.043 | 0.414–2.627 | 0.9284 | |||
| Smoking (yes vs. no) | 0.886 | 0.503–1.560 | 0.6750 | |||
| Alcohol (yes vs. no) | 0.884 | 0.494–1.580 | 0.6773 | |||
| HBsAg (positive vs. negative)a | ||||||
| HBeAg (positive vs. negative)b | 1.234 | 0.523–2.910 | 0.6307 | |||
| HBV genotype (B vs. C) | 0.583 | 0.304–1.117 | 0.1040 | |||
| HBV DNA (copies/mL) (>1×104 vs. ≤1×104)c | 1.645 | 0.934–2.895 | 0.0846 | |||
| Albumin (g/dL) (>3.8 vs. ≤3.8) | 0.551 | 0.288–1.092 | 0.0585 | |||
| AST (U/L) (>34 vs. ≤34) | 0.865 | 0.444–1.684 | 0.6691 | |||
| ALT (U/L) (>40 vs. ≤40) | 0.797 | 0.456–1.394 | 0.4267 | |||
| AFP (ng/mL) (>400 vs. ≤400) | 1.305 | 0.745–2.285 | 0.3524 | |||
| Tumor size (cm) (>5 vs. ≤5) | 1.490 | 0.863–2.572 | 0.1525 | |||
| Tumor encapsulation (yes vs. no)d | 0.901 | 0.474–1.713 | 0.7508 | |||
| Lymph node involvement (yes vs. no) | 0.333 | 0.104–1.071 | 0.0652 | |||
| Portal vein thrombosis (yes vs. no) | 1.668 | 0.600–4.633 | 0.3264 | |||
| Vascular invasion (yes vs. no) | 1.677 | 0.962–2.924 | 0.0681 | |||
| Distant metastasis (yes vs. no) | 2.259 | 0.999–5.101 | 0.0502 | |||
| Steatosis grade (2/3 vs. 0/1)e | 3.473 | 0.418–28.879 | 0.2493 | |||
| Metavir inflammation score (2/3 vs. 0/1)f | 0.731 | 0.256–2.088 | 0.5583 | |||
| Ishak fibrosis score (4/5/6 vs. 0/1/2/3)g | 1.261 | 0.670–2.373 | 0.4714 | |||
| Child-Pugh cirrhosis score (B/C vs. A) | 2.189 | 1.195–4.013 | 0.0112* | 2.065 | 1.086–3.927 | 0.0271* |
| CLIP score (4/5/6 vs. 0/1/2/3) | 2.426 | 0.328–17.911 | 0.3850 | |||
| BCLC stage (C/D vs. A/B) | 1.927 | 0.867–4.284 | 0.1077 | |||
| AJCC TNM stage (IIIA/IIIB/IIIC/IVA/IVB vs. I/II) | 4.048 | 2.123–7.719 | <0.0001*** | 3.411 | 1.710–6.804 | 0.0005*** |
| Antiviral therapy after surgery (yes vs. no) | 1.176 | 0.674–2.051 | 0.5684 | |||
| Pre-S1 del (nt 2854–2970) (yes vs. no) | 1.166 | 0.525–2.593 | 0.7059 | |||
| Pre-S1 del (nt 2855–2872) (yes vs. no) | 1.293 | 0.465–3.598 | 0.6221 | |||
| Pre-S2 del (nt 1–54) (yes vs. no) | 2.279 | 1.260–4.122 | 0.0065** | 2.392 | 1.297–4.410 | 0.0052** |
| Pre-S1+pre-S2 del (nt 2855–2872, 1–54) (yes vs. no) | 1.614 | 0.827–3.151 | 0.1604 | |||
aThere were no patients negative for HBsAg for analysis.
bOnly 71 patients with available data were analyzed.
cOnly 74 patients with available data were analyzed.
dOnly 62 patients with available data were analyzed.
eOnly 25 patients with available data were analyzed.
fOnly 44 patients with available data were analyzed.
gOnly 56 patients with available data were analyzed.
*, P value<0.05
**, P value<0.01
***, P value<0.001.
Abbreviations: HR, hazard ratio; CI, confidence interval; del, deletion; vs., versus.